Avedro, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2019; Revises Revenue Guidance for the Full Year of Fiscal 2019
May 09, 2019 at 04:07 pm
Share
Avedro, Inc. announced unaudited earnings results for the first quarter ended March 31, 2019. For the quarter, the company announced revenue was $8,773,000 compared to $5,154,000 for the same period a year ago. Loss from operations was $8,017,000 compared to $5,706,000 for the same period a year ago. Net loss was $8,353,000 compared to $6,634,000 for the same period a year ago. Net loss per share, basic and diluted was $1.00 compared to $4.85 for the same period a year ago.
The company expects revenue for 2019 to be in the range of $37 million to $40 million, representing annual growth of approximately 39% at the midpoint of the range. This compares to previous expectations for 2019 revenue to be in the range of $36 million to $40 million.
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a âsingle dose pharmaceutical,â sold primarily in conjunction with the Companyâs innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.
Avedro, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2019; Revises Revenue Guidance for the Full Year of Fiscal 2019
AVEDRO, INC. 
